Biotech startup immunitoAI has announced that it has secured $1 million in the Pi Ventures led seed funding round. The round also saw participation from existing investor Entrepreneur First.
An official statement informed, “the funds raised by the startup will be deployed for product development and industry partnerships.”
Aridni Shah, CEO and Co-founder of immunitoAI, commented, “Integration of AI with biology has become a reality today. Biology has always been difficult to study and understand, but with the use of AI, we have started to bridge the gaps and what was thought to be impossible earlier has become possible. Our vision is to make antibody therapy a norm with the help of our technology. We plan on using this seed funding to develop our AI products and validate the predictions through biological experiments.”
Speaking on the announcement, Roopan Aulakh, Managing Director, pi Ventures, added, “Our focus at pi has been to invest in startups that are revolutionizing industries using disruptive technology. This thesis is well reflected in immunitoAI, our first investment from our recently launched Fund II. The company’s AI-led platform will make the antibody discovery process faster and cheaper, enabling targeted therapy for multiple diseases. We are delighted to partner with Aridni and Trisha, who bring a unique combination of biotech and AI to the table.”
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.